Triangle Insights
@TriangleInsight
Triangle Insights Group by Mercalis is a strategy consulting firm providing guidance to leaders in life sciences organizations.
You might like
This Thanksgiving, we extend our gratitude to our clients, partners, and team members who make our work meaningful. Wishing you a season filled with joy, gratitude, and connection. Happy Thanksgiving from all of us at Triangle Insights Group.
Stay informed on the latest in drug price negotiations under the Inflation Reduction Act. Read more here: bit.ly/3VRX7oj #Pharma #DrugPricing #IRA #Healthcare
Notable developments throughout 2023, such as key approvals, regulatory updates, and advancements defined the year in Cell & Gene Therapy. Check out our recent infographic to stay informed about significant milestones from the past year: bit.ly/3ShJj4y #cellandgene #CGT
Mercalis, our parent company shares the success in 2023 including a launch of a corporate rebrand, growth of Triangle Insights Group and Policy Reporter's offerings. Patient Support Services welcomed 75 clients and provided support to 1.6 million patients. bit.ly/3tCyPmZ
In our latest white paper, we explore the implications of recently adopted regulatory policies on biopharma organizations that are developing cell and gene therapies. Download now for our insights: bit.ly/460QEdg
We are thrilled to announce that TrialCard, the parent company of Triangle Insights Group, has changed its name to Mercalis. The name change reflects the brand’s evolution into an integrated life sciences commercialization partner: mercalis.com/news/mercalis-…
We are pleased to be taking part in #BioPharmUSA this week. If you would like to discuss how we can support your commercial diligence efforts or strategic consulting needs, please book a meeting with our team via partneringONE: lnkd.in/gF-cN8ha
Our team is looking forward to a busy conference season. Coming up first are BioPharm America (Sept 13-14) and DTx East (Sept 26-28). To book a meeting, please email [email protected]. We would love to discuss how we can support your commercialization strategy.
We are delighted to announce the promotion of Sarah Jims to Partner at Triangle Insights Group. Congratulations, Sarah, and thank you for your invaluable contribution and commitment to Triangle and our clients. Read more: lnkd.in/ecuWdP7C
Today, we present the results of our 2023 Partnering Performance & Reputation Survey (PPRS). This collates anonymous feedback from biotech execs and business development leaders, with the aim of improving partnering excellence with large pharma: lnkd.in/evYS5Frs
Our latest commentary piece outlines the requirement for a clear strategy to integrate the Inflation Reduction Act (IRA) provisions into a product’s pricing, and the considerations needed for a comprehensive market access strategy. Read more: bit.ly/45MSoXN
Our Partnering Performance & Reputation Survey is now open, collating feedback from biotech execs and business development leaders around their experience of partnering with large pharmaceutical companies. Have your say in this 15-min survey before May 19: bit.ly/44BawmL
We are here at the 6th Annual Gene Therapy for Rare Disorders Summit in Boston! Email us at [email protected] if you would like to book a meeting with Sarah Jims and Brendan Smith from our team. lnkd.in/gibMw9D7 #RareDisease #GeneTherapy
Revenue forecasts for new products carry broad consequences for innovators in pharma and biotech. In this white paper, we highlight learnings from more than 100 examples of revenue forecasting and NPV analyses that we have completed in the past 8 years. bit.ly/3YOcBb0
We are pleased to be an event partner for the 6th Annual Gene Therapy for Rare Disorders Summit, taking place in Boston from March 20-23. If you are attending and would like to connect, email [email protected] to book a meeting with our team.
Our Consulting 180 PhD Program is back for 2023! From April 20-21 at our Durham, NC headquarters, doctoral candidates will have the opportunity to gain a first-hand look into life science consulting with this immersive program. Apply by March 3rd: bit.ly/3xM4Siu
During #BlackHistoryMonth, we celebrate the achievements and contributions from our Black colleagues at Triangle Insights Group. Thank you to Serwah Afranie, one of our Associate Consultants, for sharing what this month means to you. bit.ly/3y9wVK1
We're proud to sponsor the #BiotechShowcase this week, where our team has been enjoying connecting with leaders across the life science value chain. If you didn’t catch us, please email [email protected] if you would like to set up a meeting. bit.ly/3xlXRVM
We are pleased to be at #DermSummit2023 in San Francisco today. If you are in attendance and would like to connect with us, you can still book a meeting by emailing us at [email protected]. #Dermatology #JPM23
We're looking forward to attending the JPM Conference, Biotechnology Showcase & Dermatology Summit in San Francisco. If you're planning to be at #JPM23, let's connect. Book a meeting with us by emailing [email protected] or via partneringONE: bit.ly/3COzi6X
United States Trends
- 1. Pat Spencer 2,262 posts
- 2. Kerr 4,915 posts
- 3. Jimmy Butler 2,419 posts
- 4. Podz 2,951 posts
- 5. Seth Curry 3,691 posts
- 6. Hield 1,479 posts
- 7. Mark Pope 1,841 posts
- 8. #DubNation 1,352 posts
- 9. Derek Dixon 1,178 posts
- 10. Carter Hart 3,725 posts
- 11. Brunson 7,273 posts
- 12. Connor Bedard 2,136 posts
- 13. Knicks 14.3K posts
- 14. #ThunderUp N/A
- 15. Caleb Wilson 1,100 posts
- 16. Kentucky 29.6K posts
- 17. Notre Dame 38.6K posts
- 18. Jaylen Brown 8,713 posts
- 19. Celtics 16.2K posts
- 20. Kuminga 1,240 posts
You might like
-
BMJ_Open
@BMJ_Open -
Health Systems Global
@H_S_Global -
California Institute for Regenerative Medicine
@CIRMnews -
Rare Diseases
@CheckOrphan -
Color
@Color -
Frank Diana
@frankdiana -
Dr Ellie
@Dr_Ellie -
Doceree Inc
@doceree -
Delia Vlase
@DeliaVL -
Alberta Science (sometimes political) Addict
@AlbertaScience -
Tony Jones
@tony_biotech -
Mike Moore, DO FAAFP
@MikeMooreDO -
Ron Cohen, M.D.
@DrRon81
Something went wrong.
Something went wrong.